These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30698467)

  • 1. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
    Pham HT; Mesplède T
    Expert Opin Pharmacother; 2019 Mar; 20(4):385-397. PubMed ID: 30698467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
    Di Perri G
    Infez Med; 2019 Dec; 27(4):365-373. PubMed ID: 31846985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
    Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
    HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    Kityo C; Hagins D; Koenig E; Avihingsanon A; Chetchotisakd P; Supparatpinyo K; Gankina N; Pokrovsky V; Voronin E; Stephens JL; DeJesus E; Wang H; Acosta RK; Cao H; Quirk E; Martin H; Makadzange T
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):321-328. PubMed ID: 31609930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
    Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
    BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
    J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
    Rodriguez CA; Natukunda E; Strehlau R; Venter EL; Rungmaitree S; Cunningham CK; Lalloo U; Kosalaraksa P; HellstrÖm E; Liberty A; McGrath EJ; Kaur M; Leisegang R; Hindman JT; Vieira VA; Kersey K; Cotton MF; Rakhmanina N; Gaur AH
    Lancet HIV; 2024 May; 11(5):e300-e308. PubMed ID: 38621393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
    Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
    J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Negredo E; Clotet B
    Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
    Mu Y; Pham M; Podany AT; Cory TJ
    Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
    [No Abstract]   [Full Text] [Related]  

  • 19. Bictegravir.
    Spagnuolo V; Castagna A; Lazzarin A
    Curr Opin HIV AIDS; 2018 Jul; 13(4):326-333. PubMed ID: 29746268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2018 Nov; 78(17):1817-1828. PubMed ID: 30460547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.